Phase II Multicenter, Double-blinded Clinical Trial of SP160412 in the Temporary Relief of Mild to Moderate (i.e,First Degree) Sunburn
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2019
Price : $35 *
At a glance
- Drugs SP 160412 (Primary) ; Chlorphenamine; Ibuprofen
- Indications Sunburn
- Focus Therapeutic Use
- Sponsors Sephoris Pharmaceuticals
- 25 Sep 2019 Status changed from recruiting to discontinued.
- 20 Apr 2018 Status changed from not yet recruiting to recruiting.
- 01 Dec 2017 Planned End Date changed from 1 Sep 2019 to 1 Nov 2019.